Stakeholders call for local production of HIV drugs to strengthen Nigeria’s healthcare resilience

A growing chorus of health-sector stakeholders is urging the government to fast-track local manufacturing of HIV medications and related commodities, arguing that domestic production is critical to sustaining Nigeria’s HIV response. Recent statements from agencies and civil society emphasize that producing antiretroviral drugs (ARVs) and test kits locally will reduce dependence on foreign aid and ensure a steadier, more affordable supply for patients.
Among the voices championing this drive is the National Agency for the Control of AIDS (NACA), whose leadership disclosed that agreements have already been initiated to begin local manufacturing of HIV drugs and test kits before the end of 2025. The move comes as donor funding for HIV programmes declines globally, a development stakeholders warn could undermine treatment continuity if Nigeria remains reliant solely on imported supplies.
Supporters of local production argue that beyond improving access to medicines, such a step would strengthen national health security, stimulate domestic pharmaceutical capacity and create jobs.  In states such as Cross River State, officials are already exploring partnerships with local firms to manufacture ARVs — a development they say could provide lifelong treatment to thousands of residents living with HIV, and sustainably integrate HIV care into state health-insurance schemes. 
With HIV remaining a major public health challenge, stakeholders believe that homegrown production of drugs and diagnostic kits represents the most reliable path forward — one that ensures treatment is not disrupted by global funding fluctuations or supply-chain pressures.


